IL5 and eosinophilic esophagitis: There is a biologically credible mechanism that supports the use of anti-IL-5 therapy in patients with EoE due to the role of IL-5 in the maturation and release of eosinophils; a study suggested that while we witnessed a decrease in tissue eosinophilia, very few of them achieved histologic remission with < 15 eosinophils/hpf [43].